Author ORCID Identifier
Date Available
5-14-2025
Year of Publication
2023
Degree Name
Doctor of Philosophy (PhD)
Document Type
Doctoral Dissertation
College
Pharmacy
Department/School/Program
Pharmaceutical Sciences
First Advisor
Dr. Chris Delcher
Second Advisor
Dr. Val Adams
Abstract
Prostate cancer has the highest increasing rate and new cases among all cancer in men in the United States and has a higher risk in elderly men. Metastatic castration-resistant prostate cancer (mCRPC) is the late stage of prostate cancer and associated with poor prognosis (median survival 13 months). Androgen deprivation therapy (ADT) use with novel hormone therapy or standard chemotherapy are recommended for mCRPC treatment. Although, the treatment options expanded significantly in recent years, new challenges are present because of the aging population, larger treatment spectrum and co-administrated medication use for other underlying medical conditions, especially for cardiovascular disease (CVD), for several reasons. First, patients with mCRPC are more likely to be old and with pre-existing cardiovascular disease that need anticoagulants. However, enzalutamide, a commonly used novel hormone therapy, is a CYP3A4, CYP2C19, CYP2C9 inducer and has drug-drug interactions (DDIs) with certain anticoagulants and may lead to harmful effects. Secondly, cardiovascular toxicity was also reported for ADT and novel second generation of hormone therapy including abiraterone acetate and enzalutamide. This dissertation aims to better understand real-world utilization and drug safety of mCRPC treatments from different perspectives. Specifically, the objectives are 1) to characterize DDIs in treatment patterns in patients with mCRPC, 2) to characterize prescribing pattern of DDIs, using concomitant use of enzalutamide and anticoagulation as example, and 3) to compare the cardiovascular risk in patients received enzalutamide and abiraterone. The findings of this dissertation are critical in optimizing the medication use and safety and strengthening healthcare continuity for patients with mCRPC.
Digital Object Identifier (DOI)
https://doi.org/10.13023/etd.2023.222
Recommended Citation
Cheng, Yue, "POPULATION-BASED EVALUATION OF TREATMENT PATTERNS, DRUG-DRUG INTERACTIONS, AND CARDIOVASCULAR RISK IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER" (2023). Theses and Dissertations--Pharmacy. 152.
https://uknowledge.uky.edu/pharmacy_etds/152
Included in
Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons
